Phathom Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Phathom Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 54% bzw. 53.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 55.5% pro Jahr wachsen soll.

Wichtige Informationen

54.0%

Wachstumsrate der Gewinne

55.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.8%
Wachstumsrate der Einnahmen	53.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	08 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Following Up On Phathom Pharmaceuticals

Sep 03

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Jun 26

Phantom Pharma completes enrollment in late-stage study of lead candidate in esophagus inflammation disorder

Nov 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:PHAT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	371	-148	-165	N/A	6
12/31/2025	165	-299	-234	-212	7
12/31/2024	51	-345	-285	-284	6
9/30/2024	26	-339	-248	-247	N/A
6/30/2024	10	-297	-217	-215	N/A
3/31/2024	3	-247	-168	-167	N/A
12/31/2023	1	-202	-139	-138	N/A
9/30/2023	N/A	-177	-136	-135	N/A
6/30/2023	N/A	-185	-139	-138	N/A
3/31/2023	N/A	-195	-143	-141	N/A
12/31/2022	N/A	-198	-148	-147	N/A
9/30/2022	N/A	-179	-147	-147	N/A
6/30/2022	N/A	-164	-141	-141	N/A
3/31/2022	N/A	-150	-144	-143	N/A
12/31/2021	N/A	-144	-149	-148	N/A
9/30/2021	N/A	-162	-136	-135	N/A
6/30/2021	N/A	-159	-128	-127	N/A
3/31/2021	N/A	-144	-109	-108	N/A
12/31/2020	N/A	-129	-71	-70	N/A
9/30/2020	N/A	-173	-66	-65	N/A
6/30/2020	N/A	-207	-52	-51	N/A
3/31/2020	N/A	-274	-73	-47	N/A
12/31/2019	N/A	-255	-62	-37	N/A
9/30/2019	N/A	-158	-39	-13	N/A
6/30/2019	N/A	-90	-32	-7	N/A
3/31/2019	N/A	-2	-2	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PHAT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PHAT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PHAT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: PHATDie Einnahmen des Unternehmens (53.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: PHATDie Einnahmen des Unternehmens (53.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PHAT in 3 Jahren voraussichtlich hoch sein wird

Phathom Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 16%

Price target increased by 9.6% to US$24.43

Consensus EPS estimates fall by 14%, revenue upgraded

Consensus EPS estimates fall by 12%

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 45%

Recent updates

Consensus revenue estimates increase by 16%

New minor risk - Share price stability

Price target increased by 9.6% to US$24.43

Phathom Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Following Up On Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $129.999992 million.

Phathom Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $129.999992 million.

Consensus EPS estimates fall by 14%, revenue upgraded

New minor risk - Profitability

Phathom Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

President recently sold US$397k worth of stock

Phathom Pharmaceuticals Announces FDA Approval of Vquezna®? (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GermanyD in Adults

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Consensus EPS estimates fall by 12%

Phathom Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

President recently sold US$154k worth of stock

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

New minor risk - Profitability

Forecast to breakeven in 2026

Phathom Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Phathom Pharmaceuticals Announces Voquezna® (Vonoprazan) Tablets for Erosive Gerd and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Consensus revenue estimates decrease by 45%

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

New minor risk - Share price stability

Phathom Pharmaceuticals, Inc. Announces Commercial Availability of VOQUEZNA®? (Vonoprazan) Tablets

New major risk - Negative shareholders equity

Independent Director recently bought US$59k worth of stock

Phathom Pharmaceuticals, Inc. Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for Voquezna Triple Pak (Vonoprazan, Amoxicillin, Clarithromycin) and Voquezna Dual Pak (Vonoprazan, Amoxicillin) for the Treatment of H. Pylori Infection in Adults

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive Germany

Consensus EPS estimates upgraded to US$3.83 loss, revenue downgraded

New major risk - Financial position

Price target increased by 14% to US$18.67

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $130.71875 million.

Consensus EPS estimates upgraded to US$4.52 loss

President recently bought US$101k worth of stock

Consensus revenue estimates decrease by 66%, EPS upgraded

Price target decreased by 12% to US$18.20

Phathom Pharmaceuticals, Inc. Approves in the U.S. for the Treatment of H. Pylori Infection, and Its Pending New Drug Application (NDA) for Vonoprazan for the Treatment of Erosive Esophagitis

Phathom Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease

Phathom Pharmaceuticals, Inc. Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis

Price target decreased to US$26.20

High number of new directors

Phathom Pharmaceuticals, Inc. Completes Patient Enrollment in Its Phalcon-Nerd Daily Dosing Phase 3 Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease

Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

Phathom Pharmaceuticals, Inc Appoints James Topper to its Board of Directors

Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

Consensus forecasts updated

The Prognosis For Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. Announces FDA Acceptance for Filing of Vonoprazan NDA for Treatment of Erosive Esophagitis

Phathom Pharmaceuticals, Inc. Presents Data on Novel Potassium-Competitive Acid Blocker Vonoprazan from Range of Studies at Digestive Disease Week 2022

Price target decreased to US$42.80

Co-Founder & COO recently bought US$163k worth of stock

Price target decreased to US$46.20

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

High number of new and inexperienced directors

Phathom Pharmaceuticals, Inc. Appoints Frank Karbe to its Board of Directors

Phathom Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

Phathom Pharmaceuticals: Undiscovered Gem

Price target decreased to US$53.40

Forecast to breakeven in 2024

High number of new and inexperienced directors

Phathom Pharmaceuticals, Inc. Announces Results from VONO-103

Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection

Phathom Pharmaceuticals, Inc. Announces FDA Grants Additional QIDP Designations to Vonoprazan Triple Therapy and Vonoprazan Dual Therapy, Each Containing Amoxicillin Capsules, for the Treatment of H. Pylori Infection

Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter Pylori (H. Pylori) Infection; Study Met All Primary and Secondary Endpoints

Phathom Pharmaceuticals, Inc. Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial

Phathom Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $94.5 million.